Join        Login             Stock Quote

Biogen Idec (BIIB) Earnings Fall, Miss Estimates For Q4; Revenue Up 7 Pct

 January 28, 2013 06:56 AM

(By Balachander) Biogen Idec Inc. (NASDAQ: BIIB) posted a fall in quarterly earnings as higher cost and expenses offset revenue growth and the biotechnology company issued its forecast for 2013.

On a non-GAAP basis, earnings per share (EPS) declined 7.3 percent to $1.40 and missed market expectations of $1.46 for the fourth quarter.

GAAP net income attributable to Biogen Idec also decreased 2.7 percent to $292 million from the year-ago period.

Revenue rose 7 percent to $1.4 billion versus consensus estimates of $1.39 billion. Revenue from the company's multiple sclerosis (MS) drugs Tysabri and Avonex grew 10 percent and 7 percent, respectively.

[Related -Biogen Idec Inc (BIIB): Top Reasons To Own Biogen Idec]

Total cost and expenses increased 7.6 percent.

For 2012, the company earned $6.53 on a non-GAAP basis on revenue of $5.5 billion.

Looking ahead for the full year 2013, the company expects non-GAAP EPS in the range of $7.15 to $7.25 on revenue growth of roughly 10 percent. Analysts expect EPS of $7.27 on revenue of $5.98 billion.

"We are poised to begin what we expect will be a remarkable period of growth, driven by our promising compounds including TECFIDERA and Peginterferon beta-1a for MS, and both Factor VIII and Factor IX for hemophilia," commented CEO George Scangos.

The stock, which has been trading in the 52-week range of $114.53 to $157.18, closed Friday's regular trading at $146.20.

iOnTheMarket Premium


Post Comment -- Login is required to post message
Alert for new comments:
Your email:
Your Website:

rss feed

Latest Stories

article imageUS REITs Edged Higher Last Week As Emerging Markets Slumped

Real estate investment trusts (REITs) in the US took the lead in last week’s shortened holiday trading week read on...

article imageA Contrarian Perspective On The Short EuroTtrade

As the euro continues to drift lower, it has become the accepted wisdom that we are headed for parity with read on...

article imageEmerging-Markets Stocks Took The Lead Last Week

Emerging-markets equities enjoyed a solid rise last week among the major asset classes, based on a set of read on...

article imageDoes Your Latest Investment Pass This Test?

On Wednesday, I sounded the alarm about the problems looming for some consumer staples stocks. In short, read on...

Popular Articles

Daily Sector Scan
Partner Center

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.